May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Efficacy of Topical Cyclosporine versus Tears for Improving Visual Outcomes Following Multifocal IOL Implantation
Author Affiliations & Notes
  • E. Donnenfeld
    Ophthalmic Consultants of Long Island, Rockville Center, New York
  • C. Roberts
    Department of Ophthalmology, Weill Medical College of Cornell University, New York, New York
  • H. Perry
    Ophthalmic Consultants of Long Island, Rockville Center, New York
  • R. Solomon
    Ophthalmic Consultants of Long Island, Rockville Center, New York
  • J. Wittpenn
    Ophthalmic Consultants of Long Island, Rockville Center, New York
  • M. McDonald
    Ophthalmic Consultants of Long Island, Lynbrook, New York
  • Footnotes
    Commercial Relationships E. Donnenfeld, Allergan and AMO, E; C. Roberts, Allergan, E; H. Perry, Allergan, C; R. Solomon, None; J. Wittpenn, Allergan, C; M. McDonald, Allergan, C.
  • Footnotes
    Support Unrestricted grant from Allergan, Inc.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1066. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. Donnenfeld, C. Roberts, H. Perry, R. Solomon, J. Wittpenn, M. McDonald; Efficacy of Topical Cyclosporine versus Tears for Improving Visual Outcomes Following Multifocal IOL Implantation. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1066. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate the effect of topical cyclosporine A 0.05% (Restasis; Allergan, Inc.; Irvine, CA), on quality of vision in patients undergoing cataract surgery with a multifocal intraocular lens (IOL).

Methods:: A multicenter, randomized, masked, prospective clinical trial to evaluate the effect of cyclosporine A 0.05% versus an artificial tear on the quality of vision in 40 eyes of 20 patients bilaterally implanted with the ReZoom® IOL (AMO, Santa Ana, CA). Masked study medications were instilled 2 times a day for 1 month preoperatively and 2 months postoperatively in one eye and the second eye randomly received the artificial tear. UCVA, BCVA, mesopic and photopic contrast sensitivity under high-contrast and low-contrast illumination, and topography were measured unilaterally at 2 months following implantation in each eye.

Results:: At 2 months following the second eye implantation, the eyes that received the cyclosporine A had significantly improved mesopic and photopic contrast sensitivity compared to eyes not receiving cyclosporine A and there was a trend towards improved UCVA and BCVA in the cyclosporine A treated eyes.

Conclusions:: The preoperative and postoperative use of cyclosporine A 0.05% significantly improved visual outcomes in patients implanted with the ReZoom® multifocal IOL.

Clinical Trial:: www.clinicaltrials.gov NCT00349583. Registered with WIRB

Keywords: intraocular lens • drug toxicity/drug effects • cornea: tears/tear film/dry eye 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×